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antidepressants for major depression in primary
health care: a 12-month non-randomized
controlled trial (INFAP study)
Maria Rubio-Valera1,2,3*, Imma Beneitez1,4, María Teresa Peñarrubia-María2,5, Juan V Luciano1,2,4, Juan M Mendive2,6,
Paul McCrone7, Martin Knapp8, Ramon Sabés-Figuera9, Katarzyna Kocyan1, Javier García-Campayo10
and Antoni Serrano-Blanco2,11Abstract
Background: Clinical practice guidelines for the treatment of major depressive disorder (MDD) recommend
antidepressants for patients with moderate-severe depression and active monitoring for patients with mild-moderate
symptoms. The feasibility and efficiency of active monitoring has not been proven conclusively. The aim of this study is
to evaluate the cost-effectiveness of active monitoring in comparison to antidepressants for primary care patients with
mild-moderate MDD.
Methods/Design: This is a 12-month follow-up multicenter observational prospective controlled trial. Patients are
enrolled in 12 primary care centers in Barcelona (Spain). Eligible patients are adults (≥18 years-old) with a new
episode of MDD that sign a written consent to participate. This is a naturalistic study in which general practitioners
(GPs) use their professional judgment to allocate patients into active monitoring or antidepressants groups. GPs treat
the patients following their clinical criteria. At baseline, GPs complete a questionnaire (sociodemographic/job
characteristics, training, attitude towards depression, interest on mental health and participation in communication
groups). Patients’ measurements take place at baseline and after six and 12 months. Main outcome measures include
severity of depression (PHQ-9), health-related quality of life (EuroQol-5D) and use of healthcare and social care services
(Client Service Receipt Inventory). Secondary outcomes include diagnosis of MDD according to DSM-IV diagnostic
criteria (SCID-I), disability (WHO-DAS), anxiety (BAI), comorbidities, medication side-effects and beliefs about medicines
(BMQ).
The analysis will be done according to the intention to treat analysis. Missing data will be imputed using multiple
imputation by chained equations. To minimize the bias resulting from the lack of randomization, a propensity score will
be used. Incremental effects and costs between groups will be modelled in each of the imputed databases using
multivariate generalized linear models and then combined as per Rubin’s rules. Propensity scores will be used to adjust
the models. Incremental cost-effectiveness ratios will be calculated by dividing the difference in costs between groups
by the difference in effects. To deal with the uncertainty, resampling techniques with bootstrapping will be used and
cost-effectiveness planes and cost-effectiveness acceptability curves will be constructed. A series of sensitivity analyses
will be performed.
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Discussion: Given the high burden and costs generated by depressive disorder, it is important that general
practitioners treat major depression efficiently. Recent evidence has suggested that antidepressants have low benefits
for patients with mild to moderate major depression. For such cases of depression, active monitoring exists as a
treatment option, but it is not without difficulties for implementation and its effectiveness and efficiency have not been
demonstrated conclusively. The results of the study will provide information on which is the most efficient approach to
treat patients with mild to moderate major depression in primary care.
Trial registration: ClinicalTrials.gov: NCT02245373
Keywords: Depressive Disorder, Antidepressive Agents, Active Monitoring, Watchful Waiting, Costs and Cost Analysis,
Primary Health CareBackground
Major depressive disorder (MDD) generates high expend-
iture that is caused largely by its high prevalence, its recur-
rence and chronicity and because it usually affects young
people of working age [1,2]. The social cost of this mental
disorder is also very high, given the risk of suicide and the
serious negative impacts in social, occupational and family
situations [3]. From the work carried out by Goldberg and
Huxley in the eighties, it is widely recognized that major
depression is mainly treated at the primary care level [4].
More recent studies indicate that 10% to 16% of primary
care patients fulfill criteria for a diagnosis of MDD [5,6]. It
is therefore important that general practitioners (GPs) be
capable of detecting and treating MDD using evidence-
based medicine and taking the particularities of the pri-
mary level of care into account.
Psychotropic drugs, mostly antidepressants and anxio-
lytics, are highly prescribed in primary care in our setting
as they are the standard treatment for MDD. About 70% of
patients with a mood disorder receive psychotropic drugs
in Catalan primary care [7]. Moreover, almost 25% of
patients who do not fulfil criteria for a mood or anxiety
disorder are also prescribed a psychotropic drug [7]. This
percentage could include patients with minor depression or
psychological distress that the GP misdiagnosed [8,9]. A re-
view showed that benefits of antidepressants depend on the
severity of the depressive episode, which may be minimal in
patients with mild to moderate symptoms [10]. Another
review showed that brief psychological therapy (brief cogni-
tive behavioral therapy (CBT), counselling and problem
solving therapy) were effective treatments in primary care
for patients with anxiety, depression and mixed mental
health problems [11]. The recommendations of the clinical
practice guidelines for the treatment of MDD vary accord-
ing to the severity of the case. The guidelines recommend
medication for patients with moderate and severe depres-
sion and active monitoring (or watchful waiting) and refer-
ral for further assessment and interventions for those with
mild to moderate symptoms [12,13].
Active monitoring has been described as a decision
“between the clinician and the patient to not treat thecondition and to intermittently reassess its status along
some rational time course in follow-up” [14]. According
to the Catalan guideline [13], for patients receiving ac-
tive monitoring, the GP should monitor the patient
within 15 days of the first visit. Other recommendations
are to accompany closed monitoring with low intensity
psychosocial therapy (e.g. problem-solving techniques,
counselling or brief CBT), individual guided self-help
programs based on CBT or structured and supervised
exercise programs of moderate intensity. The guidelines
only recommend the use of antidepressants in mild
major depression if the patients have a history of moderate
or severe episodes of depression or if they have other
medical conditions or associated comorbidities.
Despite being recommended in guidelines, the effect-
iveness of active monitoring has not been proven con-
clusively. There has been a study showing a low
likelihood of spontaneous remission in minor depres-
sion following a one-month active monitoring period in
primary care. However, the same study showed that en-
gaging in regular pleasant activities conferred an advan-
tage to remission in minor depression.. The study
recommended the use of feasible interventions that
promote activity and decrease avoidant coping styles in
primary care [14]. Furthermore, an economic evalu-
ation of usual GP care with or without antidepressant
medication for patients with minor or mild-major de-
pression observed no differences in cost-effectiveness
between the two treatment strategies, recommendeding
that GPs sparingly prescribe antidepressants to mildly
depressed patients [15]. On the contrary, in older primary
care patients with dysthymia and minor depression, a
problem-solving behavioral based psychotherapy in
primary care showed smaller benefits for depressive
symptoms than paroxetine [16]. More recently, the
THREAD study compared selective serotonin reuptake
inhibitors (SSRIs) plus supportive care versus supportive
care alone for mild to moderate depression with somatic
symptoms in primary care [17]. The study showed that
adding an antidepressant was more cost-effective than
supportive care alone.
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the lack of consensus on what is the best strategy for im-
plementation and how to overcome the lack of adherence
to recommendations. A study examining the factors asso-
ciated with GPs’ choice of watchful waiting to care man-
agement of depression showed barriers that included the
clinicians lack of knowledge on psychotherapy and the
lack of availability of mental health professionals for refer-
ral [18]. In order to choose watchful waiting, GPs may be
able to schedule follow-up appointments with the patient
and perform low intensity psychosocial interventions or
have available referral services for the patient. However,
GPs do not routinely receive training in psychological
therapy and the adequate number of follow-up sessions
(one within the first 15 days and from six to eight during
the 10–12 weeks following the diagnosis [13]) can be un-
realistic given the existent burden in primary care. This is
illustrated by the study by Hegel and colleagues, where the
proportion of patients that received at least one contact
with the GP during the first month of watchful waiting
was of only 21% [14].
It is still necessary to show whether non-pharmacological
interventions in mild-moderate major depression can be a
feasible and cost-effective alternative compared to pharma-
cological interventions in actual practice primary care. The
aim of this study is to evaluate the cost-effectiveness of ac-
tive monitoring in comparison to the use of antidepressants
for the treatment of mild to moderate MDD in primary
care usual practice in a 12-month non-randomized con-
trolled trial.
Methods
We followed the SPIRIT statement for reporting trial proto-
cols [19]. This is the first published version of the protocol.
Study design
This is a 12 month follow-up multicenter observational
prospective controlled trial comparing patients that receive
antidepressant drugs with those who do not. The study
was approved by the Clinical Research Ethics Commitee of
the Sant Joan de Déu Foundation (CEIC Fundació SJD;
Reference Number: EPA-24-12) and the Clinical Research
Ethics Commitee of The Jordi Gol i Gurina Foundation
(CEIC IDIAP; Reference Number: 5013 – 002).
Study setting and GP enrolment
GP enrolment was conducted six months before patient
recruitment. GPs from the province of Barcelona were
invited to participate. The University Institute in Primary
Care Research Jordi Gol (IDIAP Jordi Gol), which gives
technical support to every professional that works in
Primary Care in the Catalan Public Health System,
spread the invitation to participate in the study to all
the GPs from the province of Barcelona. Furthermore,the research team contacted the Primary Care Centers
with whom they had worked in previous research studies
to invite them to participate.
The study is conducted in 12 primary care centers in the
province of Barcelona (Spain). The participating centers
have between six and 17 primary care teams (each of them
consisting of a GP and a nurse) and attend to a population
of 250,000 to 350,000 inhabitants. Sixty-eight GPs partici-
pated in the recruitment of patients for the study.
Prior to the study, GPs received a three hour-training on
the study protocol, diagnostic criteria for depression, and
national guidelines for the treatment (pharmacological and
non-pharmacological) of MDD in primary care, divided
into two 1.5-hour sessions. Session 1: Diagnosis and non-
pharmacological treatment for MDD (active monitoring,
sleep hygiene, counseling, frequency of follow-up visits,
health education and low intensity psychological therapies);
and Session 2: pharmacological treatment of MDD. During
the study, a monthly newsletter is sent to the participating
GPs to remind them of the topics presented in the training
seminars and to inform them about the study progress.
At the beginning of the study, the GPs completed a
questionnaire collecting the following variables: sociode-
mographic characteristics, job characteristics, training,
attitude towards depression, interest on mental health
and participation in communication groups [20].
Eligibility criteria and recruitment
Eligible patients are adults (≥18 years-old) who receive a
diagnosis for a new episode of MDD. The following pa-
tients are excluded: those that have taken an antidepres-
sant medication in the previous 60 days; those presenting
psychotic or bipolar disorders or on antipsychotics, lith-
ium or antiepileptics in the previous six months; those
with history of drug abuse or dependency; those with cog-
nitive impairment that prevents an assessment interview;
and those who refuse to give signed consent to participate.
GPs recruit patients for the study from their daily list
of patients attending the practice until they reach five
patients for each group (active monitoring or pharma-
cological treatment). Maximum recruiting time is
12 months. For patients meeting the inclusion criteria,
GPs inform them of the study’s aim and procedures
during the medical visit, where a written informed con-
sent is also obtained. GPs then refer patients for their
first assessment appointment.
Interventions
This is a naturalistic study. GPs use their professional
clinical judgment to recommend a treatment option to
the patient. GPs can recommend a non-pharmacological
intervention (Active Monitoring Group) or a pharmaco-
logical treatment with antidepressants (Medication Group)
following their own clinical criteria and experience.
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the usual treatment that the GPs perform when applying
active monitoring without a pharmacological treatment.
According to the Catalan guideline [13], which has been
presented to all the GPs, active monitoring requires a
first follow-up visit within the following 15 days. After-
wards, it recommends from six to eight follow-up visits
over 10–12 weeks, where the GPs can consider low
intensity psychosocial therapies such as counseling,
problem-solving techniques or on-line CBT. Also, it rec-
ommends structured and supervised exercise programs
of moderate intensity. As part of the stepped care model,
in case the patient’s condition does not improve, the GP
can intensify the treatment and initiate antidepressants.
Adherence to active monitoring is controlled through
patient interviews (patients are asked the number of con-
trol visits with the GP and the recommendations to deal
with depression from their GP). Also, at the end of the
study, the GPs will be asked to describe the actions that
were taken with patients in the Active Monitoring Group.
The patients in the Medication Group recieve the antide-
pressants usually prescribed in Spanish primary care at
doses usually recommended according to their symptoms
and characteristics. The national guidelines recommend
initiating a pharmacological treatment with SSRIs (particu-
larly with citalopram, sertraline, paroxetine or fluoxetine)
in accordance with the Catalan Health Service’s recom-
mendations following cost-effectiveness criteria [13].
Adherence to antidepressants is monitored through
two methods: pharmacy records (computerized phar-
macy records that register information about medication
including active principle, dose and units supplied in the
patient’s clinical history at the time of purchase), and pa-
tients’ self-reported adherence (with the 4-item scale de-
veloped by Morisky and colleagues [21]).
At the moment of patient inclusion, GPs complete a
form that includes the following information: patient allo-
cation (active monitoring or antidepressants) and reasons
for the allocation and type and dose of antidepressant pre-
scribed, if any. Withdrawal or changes in treatment and
the reasons (initiation of antidepressants or changes in ac-
tive principle) will be registered in another form. This will
allow the evolution of treatment in naturalistic conditions
to be monitored.
Outcomes and participant timeline
The primary outcome of the study is cost-effectiveness,
measured in terms of incremental cost per reduction of the
severity of depression achieved and in incremental costs
per quality adjusted life years (QALYs) gained. Figure 1
shows all the measures administered at each assessment
visit as well as the time schedule of patients.
Costs are collected from a societal perspective. Use of
health care resources and lost productivity are assessedusing the Client Service Receipt Inventory (CSRI) [22]
with a recall period of 12 months at baseline and six
months at point two and close-out. We collect informa-
tion on productivity losses, health tests, hospital care
(emergency visits and stays), secondary care (visits to
psychologists, psychiatrist and other specialists), primary
care (visits to GP and nurse), medication use and social
care services (visits to social worker). Information on the
use of psychotropic medicines (active principle, dose and
units supplied) is also collected from computerized
pharmacy records.
The unit costs of public healthcare services are obtained
from the Official Bulletin of the Catalan Government.
Costs of privately funded services are obtained from pub-
lished tariffs. The mean price per milligram of active
principle is calculated using the prices of the generic ver-
sions of all the presentations as reported in the Spanish
Vademecum. Productivity losses will be calculated based
on the human capital approach using information on the
minimum and average daily wage in Spain (INE) [23].
Changes in the severity of depression are assessed using
the Patient Health Questionnaire 9-item depression mod-
ule (PHQ-9) [24-26]. The PHQ-9 is a nine-item scale with
items scored from 0 (not at all) to 3 (nearly every day) on
nine symptoms of depression. Summed scores range from
0 (no depressive symptoms) to 27 (all symptoms occurring
daily). Summed scores of 20 to 27 correspond to severe
symptoms; 15 to 19 to moderately severe; 10 to 14 to
moderate symptoms; 5 to 9 to mild symptoms; and 0 to 4
to minimal symptoms.
The Spanish version of the EuroQol-5D (EQ-5D) is used
to measure health-related quality of life [27-29]. The EQ-
5D records self-reported problems in five domains (mobil-
ity, selfcare, usual activities, pain/discomfort and anxiety/
depression) divided into three levels of severity (no
problems, some problems, and extreme problems), thus
generating 245 possible health states [30]. Each state
corresponds to a single index value referred to as the
tariff. Value 1.000 is the best health state and value
0.000 corresponds to being dead. The second part records
the subject’s self-assessed health on a Visual Analogue
Scale (VAS) on which the best and worst imaginable
health states score 100 and 0, respectively. QALYs are cal-
culated by multiplying the utility with the amount of time
a patient spent in a particular health state. Linear
interpolation is used for transitions between health states.
Clinical diagnosis according to DSM-IV diagnostic cri-
teria was confirmed using the research version of the
Structured Clinical Interview for DSM-IV Axis I Disorders
(SCID-I) [31]. The modules of mood and anxiety disorders
were used. A low concordance between diagnosis of MDD
by GPs and SCID-I criteria has been described [9]. It was
considered important to check the diagnosis with SCID-I.
However, the study was naturalistic so the diagnostic
Figure 1 Schedule of enrolment, interventions and assessments. PHQ-9 = Patient Health Questionnaire; CSRI = Client Service Receipt Inventory;
BMQ= Beliefs about Medicines Questionnaire; SCID-I = Structured Clinical Interview for DSM Disorders; BIPQ = Brief Illness Perception Questionnaire;
WHO-DAS 2.0 =World Health Organization Disability Assessment Schedule; BAI = Beck Anxiety Inventory; MAQ =Medication Adherence Questionnaire.
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used as an inclusion criteria. GPs were blind to the DSM-
IV diagnosis and patient inclusion was performed accord-
ing to their usual practice.
Disability was assessed using the 12-item interviewer
administered version of the World Health Organization
Disability Assessment Schedule (12-item WHO-DAS
2.0). Respondents have to indicate the level of difficulty
experienced taking into consideration how they usually
do the activity, including the use of any assistive devices
and/or the help of a person. In each item, individuals
have to estimate the level of disability during the previ-
ous month using a 5-point scale (none = 1, mild = 2,
moderate = 3, severe = 4, extreme/cannot do = 5). The
total score is calculated with a syntax provided by theWHO can range from 0 to 100 with higher scores
reflecting greater disability. In the ERASMAP study, the
Spanish version demonstrated adequate psychometric
properties (Cronbach’s α = 0.89) and evidence of unidi-
mensionality [32-34].
The Beck Anxiety Inventory (BAI) is a twenty-one
item self-report inventory that evaluates the severity of
anxiety. Each question has four possible answer choices
that go from 0 (not at all) to 3 (severely) with total
scores ranging from 0 (minimal level of anxiety) to 63
(severe anxiety) [35,36].
Chronic physical conditions were assessed using a
“yes” or “no” check-list.
Medication Side effects: Evident side-effects are assessed
using a brief check-list considering the most common
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tensity, frequency and causal relation with antidepressant
drugs is assessed.
The Beliefs about Medicine Questionnaire (BMQ) as-
sesses the cognitive representations of medication [37,38].
It has two sections, the BMQ-General and the BMQ-
Specific. The BMQ-General evaluates general medication
beliefs and comprises two 4-item factors: General-Harm
(medicines are harmful, addictive or poisonous) and
General-Overuse (medicines are overused or excessively
trusted by doctors). The BMQ-Specific evaluates represen-
tations of specific medication prescribed for the patient, in
this case antidepressants. This part was only administered
to patients on the antidepressants group. The BMQ-
Specific comprises two 5-item factors: Specific-Necessity
(the need of antidepressants) and Specific-Concerns
(dangers of use of antidepressants).
Sociodemographic characteristics are evaluated at the be-
ginning of the study: age, gender marital status, education
and working status.
Statistical analysis
The analysis will be done according to the intention to
treat analysis (all the patients will be included in the
analysis in the group to which they were allocated inde-
pendently of the treatment they finally received.
Missing data
Missing data patterns will be evaluated to assess if it is
plausible that data is missing at random [39]. To
minimize bias resulting from the loss of information not
following a completely at random reason, missing values
will be imputed using multiple imputation by chained
equations. The imputation model will include relevant
socio-demographic and prognostic variables associated
with the drop-outs and outcome variables and variables
to be included in the final cost-effectiveness models [40].
Propensity score calculation
The allocation of patients is done according to the GP’s
decisions. Thus, it is expected to have bias, as groups
could not be comparable. To minimize the bias resulting
from the lack of randomization, we will use a propensity
score. First, it will be evaluated where the probability of
receiving active monitoring or antidepressants is affected
by GP factors (socio-demographic characteristics, job
characteristics, training, attitude towards depression,
interest on mental health and participation in communica-
tion groups) and/or patient factors (socio-demographic
characteristics, baseline severity of depression, presence of
major depression according to SCID-I criteria, severity of
anxiety, comorbid conditions and beliefs about medicines).
Second, a logistic regression model will be used to calcu-
late a propensity score. The dependent variable of thismodel will be the group (active monitoring or antidepres-
sants) and the independent variables will be those that are
associated with a higher or lower probability of receiving
active monitoring or antidepressants.
Incremental cost-effectiveness ratios calculation
Incremental effects and costs between groups will be
modelled using generalized linear models. First, different
distribution families and link functions will be tested
and Akaike and Bayesian information criterion (AIC and
BIC) will be used to decide the model that best fits the
distribution of the effects (QALYs and severity of depres-
sion) and costs. Second, to select adjustment variables,
socio-demographic and baseline clinical variables con-
sidered to be relevant will be tested in the models using
likelihood ratio tests. All the models will be adjusted for
gender, age and the propensity score. Difference in costs
and effects will be calculated using the final models in
each of the imputed databases and combined as per
Rubin’s rules [40]. Incremental cost-effectiveness ratios
will be calculated by diving the difference in costs be-
tween groups by the difference in effects.
Cost-effectiveness planes and cost-effectiveness accept-
ability curves
To deal with the uncertainty in the sampling distribution
of the incremental cost-effectiveness ratio, resampling
techniques with bootstrapping will be used. Replications
will be done in each of the imputed databases and then
combined. A minimum of 5,000 replications will be gener-
ated. Bias-corrected and accelerated (BCa) confidence in-
tervals will be estimated on each of the imputed databases
and then averaged [41]. Bootstrapped pairs of cost and ef-
fect differences will be plotted on cost-effectiveness planes
and used to construct the cost-effectiveness acceptability
curves.
Sensitivity analyses
At minimum, the following sensitivity analyses will be per-
formed: 1) an analysis from the healthcare perspective; 2) a
per protocol analysis; 3) an analysis using the mean average
salary instead of the minimum average salary for product-
ivity losses; 4) an analysis not adjusted for the propensity
score; 5) an analysis including only the patients that fulfill
DSM-IV criteria for MDD.
Sample size
In cost-effectiveness studies, sample size calculations have
been criticized and their usefulness has been questioned
[42]. This calculation is influenced by many parameters,
some of them related to costs, which must be specified a
priori. However, knowledge about costs and deviations is
scarce so it is required to make assumptions that affect
the calculation of the sample size. Moreover, this
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imum acceptable incremental cost-effectiveness ratio or
maximum willingness to pay will be. Again, where to put
the cutoff points for these parameters is a complicated de-
cision. Finally, it should be borne in mind that the results
of the economic evaluation will be presented in cost-
effectiveness acceptability curves. These curves are not
based on statistical inference so the meaning of sample
size calculations could be questioned again.
On the other hand, to deal with the uncertainty in the
sampling distribution of the incremental cost-effectiveness
ratio, it will be necessary to perform resampling tech-
niques that require a minimum sample size. Previous ex-
perience in these randomized studies with naturalistic
conditions indicates that a total of 150 patients per arm
will suffice [41,43].
Discussion
The results of this study will provide evidence about
whether active monitoring in mild-moderate MDD can be
a feasible and cost-effective alternative to pharmacological
interventions in actual practice primary care. Although
clinical practice guidelines recommend active monitoring,
evidence of its effectiveness and efficiency is scarce and
contradictory. This study will improve knowledge on ac-
tive monitoring efficiency and, as far as is known, it will be
the first study on this topic to be conducted in Spain. If
non-pharmacological interventions would prove to be
more cost-effective than pharmacological ones, this would
show that preventing the use of antidepressants in patients
with mild-moderate MDD could save the health care
system money and protect patients from side-effects of
non-necessary drugs.
The study has a series of limitations that must be con-
sidered. The naturalistic nature of the study implies the
use of wide inclusion criteria and non-randomized group
assignment, which increase the external validity of the re-
sults. However, wide inclusion criteria can increase the
inter-subject variability and reduce the ability to detect dif-
ferences. It is more likely for the GP to allocate patients
presenting with mild depression to the active monitoring
group than to the pharmacological treatment group. Con-
versely, for patients with moderate-severe depression, GPs
might be more likely to choose pharmacological options
than active monitoring. Propensity score techniques will
be used to try to minimize the impact of this bias in the
results of the study.
One limitation of the study is the GP selection. The
group of GPs that decided to participate in the study
could have a greater interest in mental health. This
might include specific attitudes of those GPs when fa-
cing physiological problems in primary care and might
not represent average GP behavior. Along these lines, it
is possible in this study that GPs enroll patients that theythink that will be more willing to participate and remain
in the study. Also, all the health centers are located in
the same health area, so the intervention can be biased
for specific practices associated to local culture or char-
acteristics of the health system.
Due to the burden of GPs, their lack of training on
brief psychotherapy techniques and the lack of referral
services available, a risk exists for active monitoring to
become no treatment at all. For example, in a trial con-
sidering a one-month watchful waiting period only 21%
of the sample had at least one contact with the physician
during the first month. To guarantee naturalistic condi-
tions in the present study, GPs received brief training on
active monitoring principles. Interventions received by
patients in the active monitoring group will be registered
to determine what active monitoring really means in
Catalan primary care real practice. Yet, non-adherence
to antidepressants in our context is high [44,45]. A sen-
sitivity analysis using a per protocol strategy of analysis
will be performed to determine the impact of the adher-
ence to the protocol both in the active monitoring and
antidepressant groups.
Another limitation could be that the GPs introduce
changes to the intervention (e.g. initiate antidepressants
for patients in the active monitoring group or change ac-
tive principle/dose in patients on antidepressants) without
filling in the study’s registration. An attempt to minimize
this will be made through monthly reminders to the GPs.
Also, the patient’s history will be reviewed to gather infor-
mation on medication.
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